Japanese journal of ophthalmology · 2026
Efficacy of ripasudil-brimonidine fixed-dose combination in secondary glaucoma associated with uveitis: a retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miyao Kenji, Imazeki Masaya, Oyama Tomoyuki, Nakai Shunsaku, Kanda Takayuki, Takeuchi Masaru
Аннотация
PURPOSE: To evaluate the intraocular pressure (IOP)-lowering efficacy and treatment stability of ripasudil-brimonidine fixed-dose combination (RBFC) in patients with secondary glaucoma associated with uveitis.
STUDY DESIGN: Single-center, retrospective study.
METHODS: Medical records of 50 eyes prescribed RBFC were reviewed and categorized into inflammatory ocular hypertension (OH; n = 19), steroid-induced OH (n = 18), and primary open-angle glaucoma (POAG; n = 13). Clinical parameters-including IOP, visual acuity (VA), and medication score-were assessed at baseline, the first follow-up, and the final visit.
RESULTS: In the inflammatory and steroid-induced OH groups, mean IOP decreased significantly from baseline and remained stable throughout the observation period (P < 0.001). VA was maintained with a slight, non-significant improvement, and medication scores remained stable, indicating sustained treatment efficacy without additional eye drops. One mild case of conjunctivitis occurred in the POAG group.
CONCLUSION: RBFC was associated with significant IOP reduction in eyes with uveitis-associated or steroid-induced OH, without compromising visual function. These findings suggest that RBFC may be a useful therapeutic option for inflammation-related secondary glaucoma.
STUDY DESIGN: Single-center, retrospective study.
METHODS: Medical records of 50 eyes prescribed RBFC were reviewed and categorized into inflammatory ocular hypertension (OH; n = 19), steroid-induced OH (n = 18), and primary open-angle glaucoma (POAG; n = 13). Clinical parameters-including IOP, visual acuity (VA), and medication score-were assessed at baseline, the first follow-up, and the final visit.
RESULTS: In the inflammatory and steroid-induced OH groups, mean IOP decreased significantly from baseline and remained stable throughout the observation period (P < 0.001). VA was maintained with a slight, non-significant improvement, and medication scores remained stable, indicating sustained treatment efficacy without additional eye drops. One mild case of conjunctivitis occurred in the POAG group.
CONCLUSION: RBFC was associated with significant IOP reduction in eyes with uveitis-associated or steroid-induced OH, without compromising visual function. These findings suggest that RBFC may be a useful therapeutic option for inflammation-related secondary glaucoma.
Предметные рубрики MeSH
HumansRetrospective StudiesBrimonidine TartrateSulfonamidesIntraocular PressureFemaleUveitisIsoquinolinesVisual AcuityAntihypertensive AgentsMaleTreatment OutcomeDrug CombinationsAgedOphthalmic SolutionsFollow-Up StudiesMiddle AgedGlaucoma, Open-AngleTonometry, OcularDose-Response Relationship, Drug